clinical trial · NCT06319456
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
CLL/SLLLisaftoclax (APG-2575)AcalabrutinibFludarabineCyclophosphamide，CTXRituximabChlorambucil
brief summary
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
started
Apr 7, 2024
primary completion
Aug 1, 2027
completion
Aug 1, 2028
last updated
May 29, 2024
detailed description
The patients with newly diagnosed CLL/SLL, who have met all required eligibility criteria, will be randomized to the investigational group (Lisaftoclax in combination with Acalabrutinib) or the control group (immunochemotherapy, CIT).
official title
A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib Versus Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol